Bluejay Diagnostics, Inc. (BJDX) stock
Close on Nov 13, 2026Market cap $2.92MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $2.92M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.39
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$7.68M
- EPS, diluted
- -$15.25
- Free cash flow
- -$6.23M
- Book value per share
- $6.35
- Diluted shares
- 1M
Trading
- Next earnings
- Mar 5, 2027 (estimated, before the open)
- Previous close
- $2.60
- Open
- $2.44
- Day's range
- $2.44 – $3.04
- Volume
- 37,030
- Average volume (20 days)
- 56,941
- Beta (5 years)
- 0.53
- 52-week range
- $0.69 – $28.00
- RSI (14 days)
- 53.0
- Volatility (1 year)
- 1409.7%
- Relative volume
- 0.05×
- WACC
- 7.8%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | BJDX | S&P 500 | Difference | BJDX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +213.6% | -3.0% | +216.6 pts | ||
| 3 months | -38.4% | -2.8% | −35.7 pts | ||
| Year to date | -2.2% | +11.5% | −13.7 pts | ||
| 1 year | -89.5% | +13.5% | −102.9 pts | ||
| 3 years | -100.0% | +77.7% | −177.7 pts | -95.1% | +21.1% |
| 5 years | -100.0% | +72.6% | −172.6 pts | -91.5% | +11.5% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Bluejay Diagnostics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Update
- Update
- Update
About Bluejay Diagnostics
Surgical & Medical Instruments & Apparatus
Bluejay Diagnostics, Inc. is a medical diagnostics company dedicated to improving patient care in critical healthcare environments, particularly for individuals diagnosed with sepsis. The company is actively developing point-of-care, rapid diagnostic tests that use whole blood samples with its proprietary Symphony technology platform. This platform comprises a specialized centrifugal analyzer and single-use protein detection cartridges designed to measure key biomarkers, with its lead product candidate focused on interleukin-6 testing. Bluejay Diagnostics intends to serve healthcare providers operating in critical care environments, with a particular focus on intensive care units and emergency rooms within acute care facilities.
Company profile, executives and historyBluejay Diagnostics stock: common questions
What is Bluejay Diagnostics's stock price?
BJDX closed at $2.61 on Nov 13, 2026, up 0.19% on the day. Over the past 52 weeks it traded between $0.69 and $28.00.
What is Bluejay Diagnostics's market cap?
Bluejay Diagnostics was worth $2.92M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is BJDX's P/E ratio?
Bluejay Diagnostics lost money over fiscal 2025 (diluted EPS -$15.25), so it has no meaningful P/E ratio.
Does Bluejay Diagnostics pay a dividend?
No. Bluejay Diagnostics has not paid a cash dividend over the last twelve months.
When does Bluejay Diagnostics report earnings next?
Bluejay Diagnostics is expected to report Q4 FY2026 results on Mar 5, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BJDX stock performed over the past year?
Including dividends, BJDX returned -89.5% over the past year, against +13.5% for the S&P 500.
Who are Bluejay Diagnostics's competitors?
Companies most similar to Bluejay Diagnostics by business, industry and size include ICU, QTEX, LUCD, CERS, CODX.
See a number that looks wrong?